REGENERON PHARMACEUTICALS, INC.
REGENERON PHARMACEUTICALS, INC. (REGN): 82 pipeline candidates · 36 upcoming catalysts · ~16 mo cash runway · 92 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
15.5 months
D/E 0.30
Lead: Phase 3
82 candidates
36 upcoming, next in ~27d
0 buys · 70 sells (180d)
A transparent, data-derived signal for REGENERON PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$64.2B
Cash
$3.0B
Quarterly Burn
$2.2B
Runway
15.5 mo
Revenue
$3.6B
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (82 candidates)
| Drug | Phase |
|---|---|
| acetylsalicylic acid | Phase 3 |
| alirocumab | Phase 2 |
| aln-5288 | Phase 1 |
| aln-ang3 | Phase 2 |
| aln-apoc3 | Phase 1 |
| aln-cfb | Phase 1/Phase 2 |
| aln-cideb | Phase 1 |
| aln-hsd | Phase 2 |
| aln-pnp | Phase 1/Phase 2 |
| aln-snca | Phase 1 |
Showing 10 of 82 candidates. Sign up for full pipeline.
Upcoming Catalysts (36)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1,390
Total value held
$65.66B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 13,309,826 | $10.28B |
| blackrock, inc. | 8,947,735 | $6.91B |
| state street corp | 4,664,478 | $3.60B |
| dodge & cox | 4,458,238 | $3.44B |
| franklin resources inc | 2,722,071 | $2.10B |
| geode capital management, llc | 2,607,732 | $2.01B |
| wellington management group llp | 1,837,459 | $1.42B |
| invesco ltd. | 1,724,478 | $1.33B |
| vanguard portfolio management llc | 1,720,774 | $1.33B |
| fmr llc | 1,518,192 | $1.17B |
Showing top 10 of 1,390 institutional holders of REGENERON PHARMACEUTICALS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in REGENERON PHARMACEUTICALS, INC.'s pipeline?
REGENERON PHARMACEUTICALS, INC. (REGN) has 82 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is REGENERON PHARMACEUTICALS, INC.'s lead drug candidate?
REGENERON PHARMACEUTICALS, INC.'s most advanced tracked candidate is acetylsalicylic acid (Phase 3) for Symptomatic Venous Thromboembolism (VTE).
What is REGENERON PHARMACEUTICALS, INC.'s next catalyst?
REGENERON PHARMACEUTICALS, INC.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of ALN-CIDEB in Adults With Fibrotic " — expected July 15, 2026.
What is REGENERON PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, REGENERON PHARMACEUTICALS, INC. has approximately 15.5 months of cash runway.
What is REGENERON PHARMACEUTICALS, INC.'s market capitalization?
REGENERON PHARMACEUTICALS, INC.'s market capitalization is approximately $64.2B.
Get the full picture on REGENERON PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.